ELREXFIO™
(elranatamab) PFIZER
Composition:1
LREXFIO™ is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, administered by subcutaneous injection.
Indication:1
ELREXFIO™ is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
References
1. ELREXFIO™. HIGHLIGHTS OF PRESCRIBING INFORMATIONUS 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf 2. FRUZAQLA™ (fruquintinib). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf 3. MOUNJARO® (tirzepatide). HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi 4. TEZSPIRE® (tezepelumab-ekko) injection. HIGHLIGHTS OF PRESCRIBING INFORMATION. US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf
